Major Bleeding With Dabigatran and Rivaroxaban in Patients With Atrial Fibrillation

What is it about?

Although the rate of bleeding among patients with atrial fibrillation (AF) taking novel oral anticoagulants in randomized controlled trials is described, the rate of bleeding with ‘‘real-world’’ use is uncertain. We conducted a retrospective electronic medical record interrogation and subsequent chart review among patients within Intermountain Healthcare between October 2010 and November 2012. We observed a rate of major bleeding similar to that reported in randomized clinical trials among patients with AF prescribed dabigatran or rivaroxaban.

Featured Image